Read by QxMD icon Read

"particle therapy"

Daniëlle Bp Eekers, Lieke In 't Ven, Erik Roelofs, Alida Postma, Claire Alapetite, Neil G Burnet, Valentin Calugaru, Inge Compter, Ida E M Coremans, Morton Høyer, Maarten Lambrecht, Petra Witt Nyström, Alejandra Méndez Romero, Frank Paulsen, Ana Perpar, Dirk de Ruysscher, Laurette Renard, Beate Timmermann, Pavel Vitek, Damien C Weber, Hiske L van der Weide, Gillian A Whitfield, Ruud Wiggenraad, Esther G C Troost
PURPOSE: To create a digital, online atlas for organs at risk (OAR) delineation in neuro-oncology based on high-quality computed tomography (CT) and magnetic resonance (MR) imaging. METHODS: CT and 3 Tesla (3T) MR images (slice thickness 1 mm with intravenous contrast agent) were obtained from the same patient and subsequently fused. In addition, a 7T MR without intravenous contrast agent was obtained from a healthy volunteer. Based on discussion between experienced radiation oncologists, the clinically relevant organs at risk (OARs) to be included in the atlas for neuro-oncology were determined, excluding typical head and neck OARs previously published...
March 13, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Sweet Ping Ng, Joseph M Herman
Pancreatic cancer is a devastating disease with poor survival outcomes. Recent studies have shown that the addition of radiotherapy to chemotherapy in the setting of locally advanced pancreatic cancer did not improve overall survival outcome. These studies commonly utilize conventional radiotherapy treatment fractionation and technique (typically 3-D conformal radiotherapy or intensity modulated radiotherapy). Although no clear benefit in overall survival was demonstrated in those studies, those who received radiotherapy did have a clear benefit in terms of local control...
March 16, 2018: Cancers
Mark T Corkum, Wei Liu, David A Palma, Glenn S Bauman, Robert E Dinniwell, Andrew Warner, Mark V Mishra, Alexander V Louie
BACKGROUND: Cancer patients frequently search the Internet for treatment options, and hospital websites are seen as reliable sources of knowledge. Guidelines support the use of proton radiotherapy in specific disease sites or on clinical trials. This study aims to evaluate direct-to-consumer advertising content and claims made by proton therapy centre (PTC) websites worldwide. METHODS: Operational PTC websites in English were identified through the Particle Therapy Co-Operative Group website...
March 15, 2018: Radiation Oncology
Alfredo Mirandola, Giuseppe Magro, Marco Lavagno, Andrea Mairani, Silvia Molinelli, Stefania Russo, Edoardo Mastella, Alessandro Vai, Davide Maestri, Vanessa La Rosa, Mario Ciocca
PURPOSE: To dosimetrically characterize a multi-layer ionization chamber (MLIC) prototype for quality assurance (QA) of pristine integral ionization curves (ICs) and spread-out-Bragg-peaks (SOBPs) for scanning light ion beams. METHODS: QUBE (De.Tec.Tor., Torino, Italy) is a modular detector designed for QA in particle therapy (PT). Its main module is a MLIC detector, able to evaluate particle beam relative depth ionization distributions at different beam energies and modulations...
March 14, 2018: Medical Physics
Angelo Castello, Laura Olivari, Egesta Lopci
Surgery, radiation therapy and chemotherapy are the oldest modalities for cancer treatment. However, as part of a continuous research in medicine, in order to improve therapeutic precision and biological effectiveness, there is an increasing interest into the use of heavy particle (e.g. protons or heavy ions) in the treatment of solid tumors. However, the restricted availability of the technology has concentrated the expertise in highly specialized centers that take care and treat extreme cases and rare pathologies...
2018: American Journal of Nuclear Medicine and Molecular Imaging
Veronica Ferrero, Elisa Fiorina, Matteo Morrocchi, Francesco Pennazio, Guido Baroni, Giuseppe Battistoni, Nicola Belcari, Niccolo' Camarlinghi, Mario Ciocca, Alberto Del Guerra, Marco Donetti, Simona Giordanengo, Giuseppe Giraudo, Vincenzo Patera, Cristiana Peroni, Angelo Rivetti, Manuel Dionisio da Rocha Rolo, Sandro Rossi, Valeria Rosso, Giancarlo Sportelli, Sara Tampellini, Francesca Valvo, Richard Wheadon, Piergiorgio Cerello, Maria Giuseppina Bisogni
Particle therapy exploits the energy deposition pattern of hadron beams. The narrow Bragg Peak at the end of range is a major advantage but range uncertainties can cause severe damage and require online verification to maximise the effectiveness in clinics. In-beam Positron Emission Tomography (PET) is a non-invasive, promising in-vivo technique, which consists in the measurement of the β+ activity induced by beam-tissue interactions during treatment, and presents the highest correlation of the measured activity distribution with the deposited dose, since it is not much influenced by biological washout...
March 6, 2018: Scientific Reports
Ján Kozempel, Olga Mokhodoeva, Martin Vlk
This review summarizes recent progress and developments as well as the most important pitfalls in targeted alpha-particle therapy, covering single alpha-particle emitters as well as in vivo alpha-particle generators. It discusses the production of radionuclides like211 At,223 Ra,225 Ac/213 Bi, labelling and delivery employing various targeting vectors (small molecules, chelators for alpha-emitting nuclides and their biomolecular targets as well as nanocarriers), general radiopharmaceutical issues, preclinical studies, and clinical trials including the possibilities of therapy prognosis and follow-up imaging...
March 5, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
Marek Pruszynski, Matthias D'Huyvetter, Frank Bruchertseifer, Alfred Morgenstern, Tony Lahoutte
Human epidermal growth factor receptor type 2 (HER2) is overexpressed in numerous carcinomas. Nanobodies (Nbs) are the smallest antibody-derived fragments with beneficial characteristics for molecular imaging and radionuclide therapy. Therefore, HER2-targeting nanobodies could offer a valuable platform for radioimmunotherapy, especially when labeled with α-particle emitters, which provide highly lethal and localized radiation to targeted cells with minimal exposure to surrounding healthy tissues. In this study, the anti-HER2 2Rs15d-nanobody was conjugated with 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid ( p-SCN-Bn-DOTA) and radiolabeled with an α-emitter225 Ac with a high yield (>90%) and a radiochemical purity above 95%...
March 5, 2018: Molecular Pharmaceutics
Seo Hee Choi, Jinsil Seong
With increasing clinical use, radiotherapy (RT) has been considered reliable and effective method for hepatocellular carcinoma (HCC) treatment, depending on extent of disease and patient characteristics. RT for HCC can improve therapeutic outcomes through excellent local control, downstaging, conversion from unresectable to resectable status, and treatments of unresectable HCCs with vessel invasion or multiple intrahepatic metastases. In addition, further development of modern RT technologies, including image-guided radiotherapy (IGRT), intensity-modulated radiotherapy (IMRT), and stereotactic body radiotherapy, has expanded the indication of RT...
February 14, 2018: Clinical and Molecular Hepatology
Gonzalez Torres Maria Jose, Henniger Jürgen
In order to expand the Monte Carlo transport program AMOS to particle therapy applications, the ion module is being developed in the radiation physics group (ASP) at the TU Dresden. This module simulates the three main interactions of ions in matter for the therapy energy range: elastic scattering, inelastic collisions and nuclear reactions. The simulation of the elastic scattering is based on the Binary Collision Approximation and the inelastic collisions on the Bethe-Bloch theory. The nuclear reactions, which are the focus of the module, are implemented according to a probabilistic-based model developed in the group...
January 2018: Physica Medica: PM
Riccardo Dal Bello, Joao Seco, Paulo Magalhaes Martins
PURPOSE: Range uncertainties limit the potential of charged particle therapy. In vivo and online range verification techniques could increase the confidence in the dose delivery distribution and lead to more conformal treatments. Prompt gamma imaging and prompt gamma spectroscopy (PGS) have been demonstrated for such purpose. The successful application of these techniques requires the development of a dedicated detector system optimized to the radiation energy ranges and the intensity...
February 7, 2018: Medical Physics
J D Lu, M Ye, Q Guo, J F Fu, X M Moyers, S T Zhang, N Y Mao, Y S Kong, X Hsi, X Y Shahnazi, J H Zhao, B Zhang, J Y Ma, Y X Z Lai, W Zhang, J Ma, L N Gao, X M Cai, S Guan, G L Zhang, J F Wu, L Cheng, Z Sheng, X M Ren, Jun Zhao, Lining Sun, Guoliang Jiang
Objective: To verify the safety and efficacy of IONTRIS particle therapy system (IONTRIS) in clinical implementation. Methods: Between 6.2014 and 8.2014, a total of 35 patients were enrolled into this trial: 31 males and 4 females with a median age of 69 yrs (range 39-80). Ten patients had locally recurrent head and neck tumors after surgery, 4 cases with thoracic malignancies, 1 case with hepatocellular carcinoma, 1 case with retroperitoneal sarcoma, and 19 cases with non-metastatic prostate carcinomas. Phantom dose verification was mandatory for each field before the start of radiation...
January 23, 2018: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
Michael R McDevitt, George Sgouros, Stavroula Sofou
α-Particle irradiation of cancerous tissue is increasingly recognized as a potent therapeutic option. We briefly review the physics, radiobiology, and dosimetry of α-particle emitters, as well as the distinguishing features that make them unique for radiopharmaceutical therapy. We also review the emerging clinical role of α-particle therapy in managing cancer and recent studies on in vitro and preclinical α-particle therapy delivered by antibodies, other small molecules, and nanometer-sized particles. In addition to their unique radiopharmaceutical characteristics, the increased availability and improved radiochemistry of α-particle radionuclides have contributed to the growing recent interest in α-particle radiotherapy...
January 18, 2018: Annual Review of Biomedical Engineering
K Ilicic, S E Combs, T E Schmid
BACKGROUND: Proton radiotherapy is a form of charged particle therapy that is preferentially applied for the treatment of tumors positioned near to critical structures due to their physical characteristics, showing an inverted depth-dose profile. The sparing of normal tissue has additional advantages in the treatment of pediatric patients, in whom the risk of secondary cancers and late morbidity is significantly higher. Up to date, a fixed relative biological effectiveness (RBE) of 1...
January 16, 2018: Radiation Oncology
Pallavi Srivastava, Asitikantha Sarma, Chandra Mohini Chaturvedi
High linear energy transfer (LET) radiation or heavy ion such as carbon ion radiation is used as a method for advanced radiotherapy in the treatment of cancer. It has many advantages over the conventional photon based radiotherapy using Co-60 gamma or high energy X-rays from a Linear Accelerator. However, charged particle therapy is very costly. One way to reduce the cost as well as irradiation effects on normal cells is to reduce the dose of radiation by enhancing the radiation sensitivity through the use of a radiomodulator...
2018: PloS One
Ying Dai, Quanxiang Wei, Christian Schwager, Janina Hanne, Cheng Zhou, Klaus Herfarth, Stefan Rieken, Kenneth E Lipson, Jürgen Debus, Amir Abdollahi
BACKGROUND: Patients with Echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) positive lung cancer are sensitive to ALK-kinase inhibitors. TAE684 is a potent second generation ALK inhibitor that overcomes Crizotinib resistance. Radiotherapy is an integral therapeutic component of locally advanced lung cancer. Therefore, we sought to investigate the effects of combined radiotherapy and ALK-inhibition via TAE684 in ALK-positive vs. wild type lung cancer cells...
January 5, 2018: Radiation Oncology
Eszter Boros, Jason P Holland
Radiometals are becoming increasingly accessible and are utilized frequently in the design of radiotracers for imaging and therapy. Nuclear properties ranging from the emission of γ-rays and β+ -particles (imaging) to Auger electron and β- and α-particles (therapy) in combination with long half-lives are ideally matched with the relatively long biological half-life of monoclonal antibodies in vivo. Radiometal labeling of antibodies requires the incorporation of a metal chelate onto the monoclonal antibody...
December 12, 2017: Journal of Labelled Compounds & Radiopharmaceuticals
Sandrine Lacombe, Erika Porcel, Emanuele Scifoni
Cancer radiation therapy with charged particle beams, called particle therapy, is a new therapeutic treatment presenting major advantages when compared to conventional radiotherapy. Because ions have specific ballistic properties and a higher biological effectiveness, they are superior to x-rays. Numerous medical centres are starting in the world using mostly protons but also carbon ions as medical beams. Several investigations are attempting to reduce the cost/benefit ratio and enlarge the range of therapeutic indications...
2017: Cancer Nanotechnology
S Giordanengo, L Manganaro, A Vignati
In the last few years, the use of ions in radiation therapy is gaining interest and it is being considered medically necessary for a growing subset of tumours. Concurrently, the technologies involved in a particle therapy treatment are rapidly evolving, as well as the accuracy in the dose delivery in spite of the increased complexity. Since nowadays, the pencil beam scanning technique is showing very interesting features in terms of dose conformation and overall treatment outcome, the present review is intended to summarize the main procedures, detectors and tools adopted for the clinical dose verification...
November 2017: Physica Medica: PM
Matthias Prall, Anna Eichhorn, Daniel Richter, H Immo Lehmann, Anna Constantinescu, Robert Kaderka, Patrick Lugenbiel, Dierk Thomas, Christoph Bert, Douglas L Packer, Marco Durante, Christian Graeff
INTRODUCTION: Whereas hadron therapy of static targets is clinically established, treatment of moving organs remains a challenge. One strategy is to minimize motion of surrounding tissue mechanically and to mitigate residual motion with an appropriate irradiation technique. In this technical note, we present and characterize such an immobilization technique for a novel noncancerous application: the irradiation of small targets in hearts with scanned carbon ion beams in a porcine model for elimination of arrhythmias...
November 2017: Physica Medica: PM
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"